Impact of delayed interval cytoreductive surgery on the survival of patients with advanced stage high-grade epithelial ovarian carcinoma

Dimitrios Nasioudis,Orlando Arevalo,Stefan Gysler,Emily M Ko,Lori Cory,Sarah H Kim,Robert L Giuntoli,Nawar A Latif
DOI: https://doi.org/10.1136/ijgc-2023-004805
2024-01-06
International Journal of Gynecological Cancer
Abstract:Objective Our objective was to use real-world data to investigate the impact of delayed interval cytoreductive surgery on the survival of patients with advanced stage high-grade ovarian carcinoma. Methods We accessed the National Cancer Database and identified patients diagnosed between 2004–2015 with advanced stage high-grade ovarian carcinoma who received neoadjuvant chemotherapy and underwent interval cytoreductive surgery. Based on timing between surgery and chemotherapy administration patients were categorized into standard (9–13.0 weeks) and delayed (13.01–26 weeks) interval cytoreductive surgery groups. Overall survival was compared with the log-rank test and a Cox model was constructed to control for a priori selected confounders. Results We identified a total of 5051 patients; 2389 (47.3%) and 2662 (52.7%) in the standard and delayed interval cytoreductive surgery groups respectively. There was no difference in complete gross resection rates (53.2% vs 54.5%, p=0.51). Patients in the delayed interval cytoreductive surgery group were less likely to undergo complex surgery (39.3% vs 45.6%, p<0.001) and had lower rates of unplanned re-admission (4.1% vs 2.6%, p=0.003). There was no difference in overall survival between the standard and delayed interval cytoreductive surgery groups, p=0.13 (median 34.3 vs 33.9 months) even after controlling for confounders (hazard ratio (HR) 1.04, 95% confidence intervals (CIs): 0.97, 1.12). There was no difference in overall survival between the two groups for patients with no gross residual (p=0.95; median overall survival 40.08 vs 39.8 months) or gross residual disease (p=0.16; median overall survival 32.89 and 32.16 months). Conclusion For patients with advanced stage ovarian cancer delayed interval cytoreductive surgery may not be associated with worse overall survival.
oncology,obstetrics & gynecology
What problem does this paper attempt to address?